文献速递乳腺癌头颈与中枢神经肿瘤

初诊时即为乳腺癌脑转移女性的预后因素及按肿瘤亚型划分的生存分析

Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
PubMed 文献 · Eur J Cancer · 2017-02-06

该研究基于2010至2013年监测、流行病学和最终结果(SEER)项目数据,纳入740例初诊即发现脑转移的乳腺癌患者,分析肿瘤亚型及其他因素对总生存(OS)的影响。全组中位OS为10个月,36个月时20.7%存活;HR+/HER2+亚型中位OS最长(22个月),三阴性中位OS为6个月。多因素分析显示年龄较大、小叶组织学、三阴性亚型、肝转移和未婚状态与更短OS显著相关。

要点

  • 初诊即脑转移乳腺癌全组中位OS为10个月,36个月时20.7%存活。
  • HR+/HER2+亚型中位OS最长(22个月),三阴性中位OS为6个月。
  • 多因素分析中三阴性亚型、肝转移、年龄较大、小叶组织学及未婚与更短OS显著相关。

核心结论

  • 初诊即乳腺癌脑转移患者总体预后差,但20.7%在诊断后3年仍存活,且不同肿瘤亚型间OS存在实质性差异。
  • 除肿瘤亚型外,诊断时年龄、婚姻状态、组织学类型和肝转移也是OS的独立预测因素。

研究设计与样本

  • 基于监测、流行病学和最终结果(SEER)项目2010至2013年报告数据的分析,纳入740例初诊即乳腺癌脑转移女性,排除其他原发恶性肿瘤患者,采用单因素和多因素分析评估各变量对总生存(OS)的影响。

主要发现

  • 全组中位OS为10个月,36个月时20.7%的患者存活。
  • 肿瘤亚型分布为激素受体(HR)+/HER2- 46.6%、HR+/HER2+ 17%、HR-/HER2+ 14.1%、三阴性22.3%。
  • 单因素分析显示肝转移、肺转移和三阴性患者(中位OS 6个月)预后更差;HR+/HER2+亚型中位OS最长,为22个月。
  • 多因素分析显示年龄较大(风险比1.8)、小叶组织学(风险比2.08)、三阴性亚型(风险比2.25)、肝转移(风险比1.6)和未婚患者(风险比1.39)OS显著更短。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The presence of brain metastases at the time of initial breast cancer diagnosis (BMIBCD) is uncommon. Hence, the prognostic assessment and management of these patients is very challenging. The aim of this study was to analyse the influence of tumour subtype compared with other prognostic factors in the survival of patients with BMIBCD. METHODS: We evaluated women with BMIBCD, reported to Surveillance, Epidemiology and End Results program from 2010 to 2013. Patients with other primary malignancy were excluded. Univariate and multivariate analyses were performed to determine the effects of each variable on overall survival (OS). RESULTS: We included 740 patients. Median OS for the whole population was 10 months, and 20.7% of patients were alive at 36 months. Tumour subtype distribution was: 46.6% hormone receptor (HR)+/HER2-, 17% HR+/HER2+, 14.1% HR-/HER2+ and 22.3% triple-negative. Univariate analysis showed that the presence of liver metastases, lung metastases and triple-negative patients (median OS 6 months) had worse prognosis. The HR+/HER2+ subtype had the longest OS with a median of 22 months. In multivariate analysis, older age (hazard ratio 1.8), lobular histology (hazard ratio 2.08), triple-negative subtype (hazard ratio 2.25), liver metastases (hazard ratio 1.6) and unmarried patients (hazard ratio 1.39) had significantly shorter OS. CONCLUSIONS: Although the prognosis of patients with BMIBCD is generally poor, 20.7% were still alive 3 years after the diagnosis. There were substantial differences in OS according to tumour subtype. In addition to tumour subtype, other independent predictors of OS are age at diagnosis, marital status, histology and liver metastases.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Leone JP, Leone J, Zwenger AO, et al. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis. Eur J Cancer. 2017. PMID: 28335884. doi:10.1016/j.ejca.2016.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。